24
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      COVID-19 vaccine hesitancy and acceptance in Mexico: a web-based nationwide survey Translated title: Aceptación y reticencia frente a la vacunación contra la COVID-19 en México: una encuesta basada en la web a escala nacional Translated title: Hesitação e aceitação em relação à vacina contra a COVID-19 no México: uma pesquisa nacional pela internet

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Objective.

          To identify factors associated with COVID-19 vaccine hesitancy and acceptance among the Mexican population.

          Methods.

          In a web-based nationwide survey in early December 2020, respondents were inquired about their sociodemographic characteristics and their willingness to accept a hypothetical COVID-19 vaccine given a 50% or 90% effectiveness. A logistic regression model was used to identify the factors associated with hesitancy and acceptance.

          Results.

          A total 3 768 responses were analyzed. A 90% effective vaccine was accepted by 85% of respondents, while only 46% would accept being vaccinated with a 50% effective vaccine. In univariate analysis, each age group (40–49, 50–59, and ≥60) was strongly associated with vaccine hesitancy for a 90% effective vaccine (OR 0.48, 95% CI 0.38, 0.63; OR 0.33, 95 CI 0.26, 0.41; and OR 0.28, 95 CI 0.21, 0.38, respectively) compared to the 18–39 age group. After multivariable adjustment, similar magnitudes of association were observed. Being female and higher socioeconomic status were also associated with higher vaccine hesitancy.

          Conclusions.

          Vaccine hesitancy represents a major public health problem in Mexico and is driven by multiple factors. Our study provides relevant insights for the development of effective policies and strategies to ensure widespread vaccination in Mexico.

          RESUMEN

          Objetivo.

          Determinar los factores asociados a la aceptación y la reticencia frente a la vacunación contra la COVID-19 en la población mexicana.

          Métodos.

          En una encuesta basada en la web a escala nacional, realizada a principios de diciembre del 2020, se preguntó a las personas entrevistadas sobre sus características sociodemográficas y su disposición a aceptar una hipotética vacuna contra la COVID-19 si garantizase 50% o 90% de efectividad. Se empleó un modelo de regresión logística para determinar los factores asociados con la aceptación y la reticencia.

          Resultados.

          Se analizó un total de 3 768 respuestas. Una vacuna con 90% de efectividad fue aceptada por 85% de las personas entrevistadas, si bien solo 46% aceptaría una vacuna con 50% de efectividad. En el análisis con una variable, cada grupo etario (de 40 a 49, de 50 a 59 y más de 60) estuvo estrechamente relacionado con una reticencia a la vacunación de una vacuna con 90% de efectividad (OR 0,48, IC de 95% 0,38, 0,63; OR 0,33, IC de 95% 0,26, 0,41; y OR 0,28, IC de 95% 0,21, 0,38, respectivamente) en comparación con el grupo etario de 18 a 39 años. Tras el ajuste multivariante, se observaron magnitudes de asociación similares. También se asoció ser mujer y tener una mejor situación socioeconómica con una mayor reticencia a la vacunación.

          Conclusiones.

          La reticencia frente a la vacunación representa un importante problema de salud pública en México y está impulsada por diversos factores. Nuestro estudio ofrece observaciones pertinentes para la elaboración de políticas y estrategias eficaces que garanticen una vacunación generalizada en México.

          RESUMO

          Objetivo.

          Identificar os fatores associados a hesitação e aceitação em relação à vacina contra a COVID-19 na população mexicana.

          Métodos.

          Em uma pesquisa nacional via internet, no início de dezembro de 2020, os participantes foram questionados acerca de suas características sociodemográficas e sua disposição de aceitar uma vacina hipotética contra a COVID-19, com eficácia de 50% ou 90%. Foi utilizado um modelo de regressão logística para identificar os fatores associados à hesitação e à aceitação.

          Resultados.

          Foi analisado um total de 3.768 respostas. Uma vacina com eficácia de 90% seria aceita por 85% dos participantes, enquanto uma vacina com eficácia de 50% seria aceita por somente 46%. Na análise univariada, cada faixa etária (40-49, 50-59, e ≥60) apresentou forte associação com hesitação em relação a uma vacina com eficácia de 90% (OR 0,48, IC de 95% 0,38, 0,63; OR 0,33, IC 95% 0,26, 0,41; e OR 0,28, IC 95% 0,21, 0,38, respectivamente), em comparação com a faixa etária de 18-39 anos. Após ajuste na análise multivariada, magnitudes semelhantes de associação foram observadas. Ser do sexo feminino e de faixa socioeconômica de renda mais alta também mostrou associação com maior hesitação em relação à vacina.

          Conclusões.

          A hesitação em relação à vacina representa um grande problema de saúde pública no México, e é impulsionada por múltiplos fatores. Nosso estudo traz informações relevantes para o desenvolvimento de políticas e estratégias efetivas para assegurar ampla vacinação no México.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

            Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A global survey of potential acceptance of a COVID-19 vaccine

              Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine. Of these, 71.5% of participants reported that they would be very or somewhat likely to take a COVID-19 vaccine, and 61.4% reported that they would accept their employer’s recommendation to do so. Differences in acceptance rates ranged from almost 90% (in China) to less than 55% (in Russia). Respondents reporting higher levels of trust in information from government sources were more likely to accept a vaccine and take their employer’s advice to do so.
                Bookmark

                Author and article information

                Journal
                Rev Panam Salud Publica
                Rev Panam Salud Publica
                rpsp
                Revista Panamericana de Salud Pública
                Organización Panamericana de la Salud
                1020-4989
                1680-5348
                18 October 2021
                2021
                : 45
                : e133
                Affiliations
                [1 ] normalizedHarvard Medical School Cambridge United States of America originalHarvard Medical School, Cambridge, United States of America
                [2 ] normalizedInstituto Tecnológico y de Estudios Superiores de Monterrey Monterrey Mexico originalInstituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico
                Author notes
                Article
                RPSP.2021.133
                10.26633/RPSP.2021.133
                8529997
                34703461
                2d9bbadd-1c16-43f7-8caf-f2ddb85c8e8c

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. No modifications or commercial use of this article are permitted. In any reproduction of this article there should not be any suggestion that PAHO or this article endorse any specific organization or products. The use of the PAHO logo is not permitted. This notice should be preserved along with the article’s original URL. Open access logo and text by PLoS, under the Creative Commons Attribution-Share Alike 3.0 Unported license.

                History
                : 04 May 2021
                : 03 August 2021
                Page count
                Figures: 2, Tables: 2, Equations: 0, References: 23
                Categories
                Original Research

                covid-19,vaccination refusal,anti-vaccination movement,mass vaccination,surveys and questionnaires,mexico,negativa a la vacunación,movimiento anti-vacunación,vacunación masiva,encuestas y cuestionarios,méxico,recusa de vacinação,movimento contra vacinação,vacinação em massa,inquéritos e questionários

                Comments

                Comment on this article